Review ArticleTreatment options in BRAF-mutant metastatic colorectal cancerBernabe-Ramirez, Carolina; Patel, Rajvi; Chahal, Jaspreet; Saif, Muhammad WasifAuthor Information Northwell Health Cancer Institute and Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, USA Received 5 December 2019 Revised form accepted 23 March 2020 Correspondence to Muhammad Wasif Saif, MD, MBBS, Northwell Health Cancer Institute, Medical Oncology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 1111 Marcus Avenue, Lake Success, NY 11042, USA, Tel: +516 321 2238; fax: +516 321 2272; e-mail: firstname.lastname@example.org Anti-Cancer Drugs: July 2020 - Volume 31 - Issue 6 - p 545-557 doi: 10.1097/CAD.0000000000000940 Buy Metrics Abstract B-type Raf kinase (BRAF) mutations occur in approximately 10% of patients with metastatic colorectal cancers (mCRC). Tumors harboring this mutation have a unique molecular profile and clinical phenotype. Response rate to systemic chemotherapy is poor and associated with shorter survival rate. Although BRAF inhibition dramatically changed treatment for melanoma patients, similar clinical responses were not observed in BRAF-mutant CRC, proposing a distinct mechanism of carcinogenesis. The aggressive biology of BRAF-mutated mCRC has underlined the importance of developing new therapeutic agents to improve outcomes in these patients. Despite numerous attempts, chemotherapy regimens are limited for this population. Reactivation of mitogen activated protein kinase pathway may explain the resistance to monotherapy, thus different combinations to target the pathway at different levels have been studied. This article will describe most suitable treatment options for CRC patients with BRAF mutation and discuss new emerging agents. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.